Stocks | | | When I think about growth stocks and possible sectors to target for growth the Communication Services sector does not spring instantly to mind. What the hum-drum name hides though, is a basket of high-growth tech names most investors would love to own.
According to data from Factset the Communicati... Read the Full Story |
|
From Our PartnersLocated just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And on December 31st it comes online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market. | | Click here for more. |
|
Markets | | | Kroger’s (KR)management made two major missteps with the Restock Kroger plans. The first was their overaggressive plans to grow business in an attempt to compete with Walmart (WMT), Target (TGT), and Amazon (AMZN). The second was failing to realize the mistake soon enough. Now, with the compet... Read the Full Story |
|
Stocks | | |
Shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) changed hands in heavy trading on Wednesday after the company announced an equity offering before the market opened. Having reported earnings last week that smashed estimates and sent the stock to all-time highs, this was a nasty surprise to inves... Read the Full Story |
|
From Our PartnersA star has broken out of the gloomy legal marijuana investing sector. It’s a young company in a market that’s grown nearly 3,000% in the past three years. That’s why revenues are up 2,269%. The company is in Washington State. It’s a rock-solid market – the world’s second oldest – with its growing pains behind it. | | It’s Why You Should Target This Penny Stock Now |
|
Markets | | |
It's a pretty good time to be Target (NYSE: TGT) right now. With a very good chance at being declared “king of the internet” based on our earlier projections—we considered it “late to the show” but representing part of a competitive landscape that's rapidly increasing... Read the Full Story |
|
Markets | | |
Over the holiday weekend, I noticed that a new Dollar General (NYSE:DG) store was getting ready to open in my area. I had heard that DG was one of the few retailers that were opening stores, so that wasn’t a surprise. However, it was surprising that this store wasn’t being built to rep... Read the Full Story |
|
From Our PartnersFormer Lehman Brothers executive reveals one of Wall Street's best kept secrets. A proven system for turning $1,000 into $1.3 Million (or more) -without touching the stock market.
In fact, this system is responsible for the most profitable investment of all time! | | Click here for details >> |
|
The Early Bird Stock Of The Day Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
